1047637-17-1

Basic information

• Product Name: 1,4-dimethyl-5-(tri-n-butylstannyl)-1H-1,2,3-triazole
• Synonyms: 1,4-dimethyl-5-(tri-n-butylstannyl)-1H-1,2,3-triazole
• CAS NO: 1047637-17-1
• Molecular Weight: 386.168
• Mol File: 1047637-17-1.mol

Chemical Properties

• CAS DataBase Reference: 1,4-dimethyl-5-(tri-n-butylstannyl)-1H-1,2,3-triazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-dimethyl-5-(tri-n-butylstannyl)-1H-1,2,3-triazole(1047637-17-1)
• EPA Substance Registry System: 1,4-dimethyl-5-(tri-n-butylstannyl)-1H-1,2,3-triazole(1047637-17-1)

Safety Data

• Hazardous Substances Data: 1047637-17-1(Hazardous Substances Data)

Usage

Chemical structure

A chemical compound with a triazole ring structure and three n-butylstannyl groups attached to the carbon atom.

Common use

Used in organic synthesis and as a reagent for the preparation of various functionalized triazoles.

Intermediate

The presence of the tri-n-butylstannyl groups makes it a useful intermediate in the preparation of other organic compounds and materials.

Application in medicinal chemistry

Utilized in the design and synthesis of potential pharmaceuticals.

Application in agrochemical research

Used in the design and synthesis of potential pesticides.

Unique structure and reactivity

Its unique structure and reactivity have led to its investigation for potential applications in materials science and nanotechnology.

Upstream product

• 1461-22-9 tributyltin chloride 
• 60166-43-0 1,4-dimethyl-1H-[1,2,3]triazole 

Relevant articles and documents

ATR INHIBITORS AND USES THEREOF

The present disclosure relates to novel compounds useful as inhibitors of ATR kinase, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.

TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF

The present applicationpresent application relates to a compound represented by Formula (III) or a pharmaceutically acceptable salt, solvent compound, active metabolite, crystal polymorph, ester, isomer, or prodrug thereof. The application further provides a pharmaceutical composition comprising the compound represented by Formula (III) and a use thereof for preparing a bromodomain inhibitor for preventing or treating various diseases, such as inflammation and cancer, related to the bromodomain.

EZH2 Inhibitors

The present invention relates to compounds that inhibit EZH2 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.